MassMutual Private Wealth & Trust FSB Has $2.19 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

MassMutual Private Wealth & Trust FSB grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 26,389.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,748 shares of the specialty pharmaceutical company's stock after acquiring an additional 17,681 shares during the period. MassMutual Private Wealth & Trust FSB's holdings in Jazz Pharmaceuticals were worth $2,186,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Pacer Advisors Inc. grew its position in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after acquiring an additional 278,465 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Jazz Pharmaceuticals by 48.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company's stock worth $130,447,000 after purchasing an additional 398,549 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock valued at $124,208,000 after purchasing an additional 48,708 shares during the period. Thompson Siegel & Walmsley LLC raised its holdings in shares of Jazz Pharmaceuticals by 8.3% during the third quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company's stock valued at $87,035,000 after buying an additional 59,685 shares during the last quarter. Finally, Perpetual Ltd boosted its position in shares of Jazz Pharmaceuticals by 10.4% during the third quarter. Perpetual Ltd now owns 675,431 shares of the specialty pharmaceutical company's stock worth $75,250,000 after buying an additional 63,564 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on JAZZ shares. Royal Bank of Canada reissued an "outperform" rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday, November 18th. Needham & Company LLC reissued a "buy" rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Morgan Stanley raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Finally, TD Cowen dropped their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $177.00.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares of the company's stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,253 shares of company stock worth $1,001,434. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

JAZZ traded down $0.06 during midday trading on Tuesday, reaching $121.12. The company's stock had a trading volume of 256,623 shares, compared to its average volume of 461,570. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The stock has a market cap of $7.32 billion, a P/E ratio of 17.03, a PEG ratio of 0.88 and a beta of 0.56. The company has a fifty day simple moving average of $122.66 and a 200 day simple moving average of $114.87. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.